New drug BC006 aims to slow lung scarring in IPF patients
NCT ID NCT07447102
First seen Mar 03, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study tests a new drug called BC006 in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The trial has two parts: first, a small group gets BC006 to check safety, then a larger group is randomly assigned to receive either BC006 or a placebo for 24 weeks. The main goal is to see if BC006 improves lung function and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.